Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- January 21, 2022
- Completion date
- December 21, 2026
- Enrollment
- 150 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
her2-positive advanced solid tumors